// App-Quantinova.ai

: YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update

Researchers

Presenter

  • Pere Barba

Principal Investigators

  • Javier Briones

  • Ulrich Jaeger

  • Emmanuel Bachy

  • Didier Blaise

  • Nicolas Boissel

  • Koji Kato

  • Nirav N. Shah

  • Matthew Frigault

  • Peter A. Riedell

  • Leyla O. Shune

  • Takanori Teshima

  • Fabio Ciceri

  • David Pearson

  • Elena J Orlando

  • Lan Yi

  • Jaclyn Davis

  • Aisha Masood

  • Ian W. Flinn

  • Michael Dickinson

Medical Centers

  • The University of Kansas Medical Center, Kansas City, KS

  • Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan

  • Department of Hematology, Institute of Health Research Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain

  • Novartis Institutes for BioMedical Research, Basel, Switzerland

  • Novartis Institutes for BioMedical Research, East Hanover, NJ

  • Hematology Department, Hospital Universitari Vall d'Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain

  • Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan

  • Hospices Civils de Lyon and Université Claude Bernard Lyon , Lyon, France

  • Medical College of Wisconsin, Milwaukee, WI

  • Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Australia

  • Department of Hematology, Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • Département d'hématologie, Programme de transplantation et de thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Aix-Marseille University, Institut Paoli Calmettes, Marseille, France

  • Department of Medicine, The University of Chicago, Chicago, IL

  • Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy

  • Hematology Adolescent and Young Adult Unit, Saint-Louis Hospital, Paris, France

  • Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

  • Novartis Institutes for BioMedical Research, Cambridge, MA

  • Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Vienna General Hospital - Medical University of Vienna, Vienna, Austria

  • Massachusetts General Hospital, Dorchester, MA

Locations

  • United States

  • Spain

  • Japan

  • France

  • Austria

  • Switzerland

  • Italy

  • Australia

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Lymphomas

Biomarkers

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved